Literature DB >> 7241672

Results of inferior vena cava resection for renal cell carcinoma.

G P Kearney, W B Waters, L A Klein, J P Richie, R F Gittes.   

Abstract

A total of 24 patients with renal cell carcinoma involving the inferior vena cava underwent thoracoabdominal radical nephrectomy with removal of tumor thrombus by an open or closed technique. The tumor extended in the inferior vena cava to the level of the renal or lower hepatic veins in 18 patients and it reached the level of the diaphragm or right atrium in 6. Of the 24 patients 3 with preoperative findings minimally suggestive of disseminated disease were shown later to have metastases in the questionable areas, 3 with disease at the level of the diaphragm had incomplete resections, 4 had metastases to regional lymph nodes and 1 had questionable preoperative findings and lymph node metastases. Only 13 of the 24 patients (54 per cent) did not have either disseminated or residual tumor postoperatively. The mean survival duration of this subgroup (20 months) was comparable to that of the group as a whole (21 months). However, 4 patients from this subgroup are free of disease, with a mean followup of 30 months. There was 1 postoperative death. Morbidity, including renal failure, intraoperative hypotension and sepsis, was common. The results in this series suggest that the prognosis for patients with renal cell carcinoma and inferior vena cava involvement is guarded.

Entities:  

Mesh:

Year:  1981        PMID: 7241672     DOI: 10.1016/s0022-5347(17)55199-x

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  15 in total

1.  Resection and reconstruction of the inferior vena cava for neoplasms.

Authors:  Nikola Nikolov Vladov; Vassil Ivanov Mihaylov; Nikolai Vassilev Belev; Ventzislav Metodiev Mutafchiiski; Ivelin Rumenov Takorov; Sergei Kirilov Sergeev; Evelina Hristova Odisseeva
Journal:  World J Gastrointest Surg       Date:  2012-04-27

2.  Surgical treatment of renal cell carcinoma with a tumor thrombus extending into the right atrium.

Authors:  S Taniguchi; S Kitamura; K Kawachi; T Nishii; M Fukutomi; Y Hamada; E Okajima
Journal:  Heart Vessels       Date:  1990       Impact factor: 2.037

3.  Intra-atrial extension of renal and adrenal tumors: diagnosis, management, and prognosis.

Authors:  T B Hugh; R M Jones; M X Shanahan
Journal:  World J Surg       Date:  1986-06       Impact factor: 3.352

4.  Surgical management of renal cell carcinoma with inferior vena caval and right atrial involvement.

Authors:  T Muraguchi; K Sakai; T Yamada; N Usui; Y Tsukamoto; E Kimura; K Esaki; S Ikemoto
Journal:  Jpn J Surg       Date:  1985-09

5.  Renal-cell carcinoma with intracaval neoplastic extension: stratification and surgical technique.

Authors:  C G Stief; H J Schäfers; M Kuczyk; P Anton; K Pethig; M C Truss; U Jonas
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

6.  Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib.

Authors:  Lauren C Harshman; Sandy Srinivas; Aya Kamaya; Benjamin I Chung
Journal:  Nat Rev Urol       Date:  2009-06       Impact factor: 14.432

7.  Suprarenal vena caval occlusion. Principles of operative management.

Authors:  B M Smith; J L Mulherin; J L Sawyers; B I Turner; R L Prager; R H Dean
Journal:  Ann Surg       Date:  1984-06       Impact factor: 12.969

8.  Cardiovascular surgery in the management of malignant renal neoplasms: survey of 187 cases in the literature.

Authors:  D C Schechter
Journal:  Tex Heart Inst J       Date:  1983-06

9.  Vena caval involvement by renal cell carcinoma. Surgical resection provides meaningful long-term survival.

Authors:  D G Skinner; T R Pritchett; G Lieskovsky; S D Boyd; Q R Stiles
Journal:  Ann Surg       Date:  1989-09       Impact factor: 12.969

10.  Surgical treatment of inferior vena cava tumor thrombus in patients with renal cell carcinoma.

Authors:  Tae-Won Kwon; Hyangkyoung Kim; Ki-Myung Moon; Yong-Pil Cho; Cheryn Song; Chung-Soo Kim; Hanjong Ahn
Journal:  J Korean Med Sci       Date:  2009-12-26       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.